Skip to content

Author

E. Bugianesi

7 papers indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Nov 2026

New CLA3+/4 scores predict outcomes in MASLD.

BACKGROUND & AIMS Fibrosis is a major determinant of adverse outcomes in metabolic dysfunction-associated steatotic liver disease (MASLD). We developed and validated two probability scores for advanced fibrosis (≥F3) and cirrhosis (F4)-CLA3+ and CLA4-using controlled attenuation parameter (CAP), liver stiffness (LS) by...

Dong Hyun Kim, N. Cho, Terry Cheuk-Fung Yip et al. · 0 citations
Sep 2026

Personalised prediction of the individual risk of liver-related events in MASLD using the dynamics of non-invasive tests.

By automatically integrating and interpreting the dynamics of non-invasive tests of liver fibrosis, JLCM enables the personalised prediction of the risk of hard outcomes, rather than the imperfect evaluation of histological surrogates.

C. Moreau, M. Roux, J. Riou et al. · 1 citation
Open access Sep 2026

Stratified Use of Genetic Testing in Liver Disease Improves Diagnostic Yield and Clinical Impact

It is demonstrated that tailoring genetic testing strategies to patient age and clinical presentation can improve diagnostic efficiency and support a standardized integration of genetic testing into hepatology practice.

A. Faini, Michele Pinon, Giulia Margherita Brach del Prever et al. · 0 citations
Aug 2026

Chicken bone-derived peptides: characterization and effects on human gut microbiota using the Simulator of the Human Intestinal Microbial Ecosystem (SHIME®).

Findings support the use of chicken bone-derived collagen peptides as a promising strategy to modulate gut microbiota ecology and metabolic outputs.

Rebeka Correia de Souza Cunha, I. Franciosa, Viviane Maria de Sousa Fontes et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.